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Abstract
Background Adenosine kinase deficiency is a recently de-
scribed defect affecting methionine metabolism with a severe
clinical phenotype comprising mainly neurological and hepat-
ic impairment and dysmorphism.
Methods Clinical data of 11 additional patients from eight
families with adenosine kinase deficiency were gathered
through a retrospective questionnaire. Two liver biopsies of
one patient were systematically evaluated.
Results The main clinical symptoms are mild to severe liver
dysfunction with neonatal onset, muscular hypotonia, global
developmental retardation and dysmorphism (especially fron-
tal bossing). Hepatic involvement is not a constant finding.
Most patients have epilepsy and recurrent hypoglycemia due
to hyperinsulinism.Major biochemical findings are intermittent
hypermethioninemia, increased S-adenosylmethionine and S-
adenosylhomocysteine in plasma and increased adenosine in
urine. S-adenosylmethionine and S-adenosylhomocysteine are
the most reliable biochemical markers. The major histological
finding was pronounced microvesicular hepatic steatosis. Ther-
apeutic trials with a methionine restricted diet indicate a poten-
tial beneficial effect on biochemical and clinical parameters in
four patients and hyperinsulinism was responsive to diazoxide
in two patients.
Conclusion Adenosine kinase deficiency is a severe in-
born error at the cross-road of methionine and adeno-
sine metabolism that mainly causes dysmorphism, brain
and liver symptoms, but also recurrent hypoglycemia.
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The clinical phenotype varies from an exclusively neu-
rological to a multi-organ manifestation. Methionine-
restricted diet should be considered as a therapeutic
option.
Introduction
The essential amino acid methionine is next to protein
synthesis involved in fundamental biological processes.
The transmethylation of methionine to homocysteine is
present in all mammalian cells and its disruption can lead
to severe clinical phenotypes (Baric 2009). Defects of the
single steps of the methionine cycle are MAT I/III defi-
ciency (OMIM #250850) (Chien et al 2015), GNMT de-
ficiency (OMIM #606664) (Mudd et al 2001) and SAHH
deficiency (OMIM #613752) (Baric et al 2004). Homo-
cysteine and adenosine are the products of the hydrolysis
of S-adenosylhomocysteine (AdoHcy). Cystathionine
beta-synthetase (CBS) mediates the first step of the
breakdown of homocysteine and causes classical
homocystinuria if deficient (OMIM #236200) (Mudd et
al 1964). Adenosine kinase (ADK) converts adenosine to
AMP, and a defective function of the enzyme leads to an
accumulation of adenosine. This disrupts the methionine
cycle by a reversal of the reaction balance of SAHH (Boison et
al 2002, 2010). causing elevated concentrations of AdoHcy,
S-adenosylmethionine (AdoMet) and methionine (Fig. 1).
In 2011, Bjursell et al described the first six patients
from three families with autosomal-recessive ADK defi-
ciency (OMIM #614300), that were characterized by
global developmental retardation, epilepsy, liver dys-
function, dysmorphic features and hypermethioninemia
(Bjursell et al 2011).
Adenosine is pivotal for maintenance of energy ho-
meostasis in most organ systems including the brain
(Newby et al 1985) and is an endogenous modulator
of neuronal excitability (Dunwiddie 1980; Fredholm
and Hedqvist 1980). AdoHcy is a powerful inhibitor
of most methylation reactions that play a pivotal role
in metabolism (Blom et al 2006). including epigenetic
DNA methylation. ADK inhibitors and deficiency of
ADK were shown to induce hypomethylation of DNA
via biochemical interference with the transmethylation
pathway in mice (Williams-Karnesky et al 2013). As
may be expected from the importance of this pathway,
autosomal-recessive ADK deficiency comprises a com-
plex inborn error of metabolism with a severe clinical
phenotype. So far, no specific therapeutic approach is
known. This study of a greater number of individuals
with ADK deficiency reveals new insights into this
disease.
Materials and methods
Study design
Clinical data of 11 patients from eight families identified with
ADK deficiency were collected by a questionnaire, including
anthropometrical data, first symptoms, clinical symptomatol-
ogy, laboratory findings, as well as results of liver and muscle
biopsies, and effects of dietary interventions. Written in-
formed consent was obtained from all parents. For detailed
case reports, see the Supplementary Appendix. Patients 9
and 10 have been identified to carry a homozygous mutation
in ADK through a large next generation sequencing study in
individuals with intellectual disability (Najmabadi et al 2011).
published practically at the same time (October 2011) as the
Fig. 1 Transmethylation of methionine to homocysteine and adenosine
degradation. Via AdoMet and AdoHcy methionine is converted to
homocysteine (Hcy), which can be remethylated back to methionine.
AdoMet functions as donor of methyl-groups in a wide range of
transmethylation reactions. SAHH hydrolyses AdoHcy into adenosine
and Hcy. These products are under normal conditions constantly
removed, preventing the accumulation of AdoHcy because the
equilibrium of SAHH favours AdoHcy synthesis. There are two
metabolic pathways that remove adenosine: the deamination into
inosine via adenosine deaminase (ADA; EC 3.5.4.4) and the
phosphorylation into AMP via adenosine kinase (ADK; EC 2.7.1.20).
ADK has a low Km for adenosine, and is considered to be the main
route of adenosine metabolism. In ADK deficiency, adenosine
accumulates, reversing the reaction of SAHH to the condensation of
AdoHcy. Via inhibition of transmethylation reactions, AdoHcy
accumulation leads to an increase of AdoMet and finally methionine.
Apart from ADK deficiency, deficiencies of MAT I/III, GNMT, SAHH
and CBS are known inborn errors of metabolism of the transmethylation
pathway. Deficiency of ADA causes severe combined immunodeficiency
(SCID) (#OMIM 102700). Adapted from The American Journal of
Human Genetics, Vol 89, Magnus K. Bjursell, Henk J. Blom, et al,
507-515, 2007, with permission from Elsevier
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initial description of ADK deficiency by Bjursell et al
(Bjursell et al 2011). Apart from intellectual disability no de-
tails on the clinical course of the two patients have been pub-
lished before. Material was not available for measurement of
biochemical parameters (methionine, AdoMet and AdoHcy,
total homocysteine, adenosine) in patients 9 and 10.
Liver histopathology
Paraffin-embedded blocks of two liver biopsies of patient 2
were further analysed with immunohistochemistry and ultra-
structural pathology. For immuno-histochemical analysis of
steatosis, primary antibodies against lipid droplet-associated
proteins of the perilipin family were used as described previ-
ously (Straub et al 2008; Pawella et al 2014). For ultrastruc-
tural pathology, biopsies were fixed in glutaraldehyde and
embedded in epon. Thin sections were analysed in a transmis-
sion electron microscope (JEM 1400, JEOL).
Measurements of AdoMet and AdoHcy in plasma
and CSF and of adenosine in dried blood spots
AdoMet and AdoHcy were measured in plasma and CSF via a
stable-isotope dilution liquid chromatography-electrospray
tandem mass spectrometry method, as published before
(Gellekink et al 2005). Likewise, adenosine concentration in
dried blood spots were measured via a stable-isotope dilution
liquid chromatography-electrospray tandem mass spectrome-
try method, see reference (Azzari et al 2011) for details.
Methionine loading test
In patient 8, a methionine loading test was performed at the
age of 7 years. Concentrations of methionine were determined
in plasma before and 4, 6 and 12 hours after application of L-
methionine (0.1 g/kg body weight, oral administration).
Results
Variable and extending clinical phenotype
Since the first publication of ADK deficiency in 2011,
we identified 11 new patients from eight families. Apart
from family VII, all patients became symptomatic in the
newborn period. First symptoms were mainly severe or
prolonged conjugated hyperbilirubinaemia and hypogly-
cemia. In the course of the disease, muscular hypotonia
and developmental delay were noticed in all individuals
within the first year of life or shortly after. Severity of
developmental delay varied from moderate to severe in-
tellectual disability. Most patients developed epileptic
seizures with onset (first afebrile seizure) between
4 months and 8.1 years (mean age of onset 27.4 months).
EEG showed no significant abnormalities in the four pa-
tients without epilepsy. Whereas hyperbilirubinaemia was
most prominent in the newborn period, all patients ex-
cept patients 9 and 10 (family VII) had intermittent in-
creases of transaminases and/or cholestasis in the further
course, ranging from mild hepatopathy to liver failure.
Hepatopathy tended to be less severe with increasing
age. No trigger of liver crises was unambiguously iden-
tified. Some patients had intermittent hepatomegaly.
Nine patients had recurrent hypoglycemia, four already in
the neonatal period. In three patients, hyperinsulinism was
identified as the underlying cause, whereas it was not studied
in most other cases. Two patients were treated with diazoxide
with good response. Frontal bossing was present in all pa-
tients, whereas hypertelorism, sparse and thin hair, abnormal
dentition, marfanoid features such as slender hands and feet,
macrocephaly, short stature and failure to thrive were
present in some. Five patients had cardiac defects, most
of them were mild. Four patients developed cholelithiasis
and three had megaloblastic anemia (see Table 1, Fig. 2
and in the Supplementary Appendix case reports and
Table S1 for further details). Megaloblastic anemia could
be due to reduced 5-methyltetrahydrofolate concentra-
tions, possibly as a consequence of inhibition of
methylentetrahydrofolate reductase activity due to the in-
creased AdoMet concentrations. Muscle biopsy was per-
formed in one patient (patient 2, biopsy at the age of
1 month) with normal results on light microscopy. There
was no mitochondrial DNA depletion and pyruvate de-
hydrogenase complex activity was normal.
Genotype
In 11 patients from eight families, seven new mutations of the
ADK gene were identified (six families homozygous, one fam-
ily compound heterozygous; see Table 1). Numbering is based
on the short (cytosolic) isoform of ADK (isoform a; transcript
NM_001123.3; protein NP_001114.2). Types of mutations
are as follows: deletion (1), frameshift (1), nonsense (2) and
missense (3). All missense mutations are predicted to be pos-
sibly or probably damaging as predicted by “PolyPhen-2”
(Score 0.87 – 1.0) (Adzhubei et al 2010). whereas all missense
mutations are predicted to be disease causing using BMutation
taster^ (Score 1.0) (Schwarz et al 2014). All mutations are
extremely rare: none of the variants are listed in the 1000
Genome project, whereas one heterozygous allele carrier for
c.250C>T, p.Gln84* and two heterozygous allele carriers for
c.953C>A, p.Ala318Glu are listed in the Exome Aggregation
Consortium (ExAC) Server (Cambridge, MA [10/2015]), that
includes variants from >120.000 alleles of unrelated
individuals.
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Biochemical phenotype
Metabolic workup revealed hypermethioninaemia in all pa-
tients. However, methionine levels in plasma vary and may
even lie within the normal range (see Table 2 and Fig. S1). In
contrast, concentrations of AdoMet and AdoHcy in plasma
were always elevated, even when methionine concentrations
were normal (e.g. patient 2 at the age of 6.8 years: methionine
42 μmol/L (reference range 15-45 μmol/L), AdoMet
212 nmol/L (reference range 71-118 nmol/L), AdoHcy
154 nmol/L (reference range 9.3-14 nmol/L, all in plasma)).
Adenosine concentrations in urine were only slightly elevated
or in the upper normal range in some patients examined. In
patient 2, adenosine concentrations varied from normal
(1 mmol/mol creatinine) to clearly elevated (22 mmol/mol
creatinine, reference range <4 mmol/mol creatinine) (see
Table 2 for further details). Some patients have mildly elevat-
ed concentrations of total homocysteine (tHcy), which could
be explained by decreased homocysteine remethylation due to
inhibition of methylentetrahydrofolate reductase by AdoMet.
Consistent or recurrent mild hyperammonaemia was de-
scribed during the first months of life in patients 1 and 11,
but has remained unexplained.
Methionine loading test in patient 7 revealed the following
methionine concentrations in plasma: 0 h: 30 μmol/L; 4 h:
441 μmol/L; 6 h: 694 μmol/L and 12 h: 570 μmol/L. In
healthy subjects, methionine reaches it maximum between
0.5 to 1 hour after loading (Blom et al 1989, 1992). In contrast,
in the ADK patient examined the peak was reached at 6 hours,
which indicates a decreased uptake from the gut and/or de-
layed passage through the liver. The still greatly increased
methionine concentration at 12 hours after loading points at
a delayed conversion of excess methionine.
Metabolites measured in newborn screening dried blood
spots
Methionine was measured in newborn screening DBS of three
patients. Methionine concentration was normal in one case
and mildly elevated in two cases (96 μmol/L and 138 μmol/
L), but one of those two had a normal methionine concentra-
tion in the control sample seven days later (at the age of
10 days). Adenosine was measured in two newborn screening
DBS and was clearly elevated in both (adenosine 3.78 and
3.82 μmol/L, respectively; normal <1.0).
Low methionine diet
Seven patients received a low methionine diet consisting of a
reduction of the daily intake of methionine to 15-20 mg per kg
of body weight. In patient 2 the diet was initiated during the
newborn period but was discontinued after 5 days due to lack
of clinical and biochemical response. Patient 5 did not tolerateTa
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methionine free formula as she developed intractable diar-
rhoea even with changing the diet to a different type of me-
thionine free formula, and the parents decided to stop the
dietary treatment. In patient 8 the diet was stopped after one
year (at the age of 4.25 years) because it was considered inef-
fective. In contrast, patients 3, 4, 6 and 7 showed clear im-
provement of clinical and/or biochemical parameters after the
start of a lowmethionine diet. Patient 6 has been treated with a
low methionine diet since birth. Discontinuation of the diet
resulted in acute deterioration of liver function at the age of
20 years, which was reversible after reintroduction of dietary
treatment. Also in patients 3 and 7 improvement of liver func-
tion was noted (see Fig. S1 and Table S2) and in addition, the
frequency of hypoglycaemic episodes decreased. In patient 7,
moreover a striking improvement of the neurological pheno-
type with amelioration of developmental delay, motor func-
tion and speech was observed. In all patients (except patient 2,
who was only treated for 5 days) a clear biochemical response
with decrease or normalization of methionine levels and de-
crease of AdoMet and AdoHcy concentrations in plasma was
noted under therapy. In addition, in patient 7 a decrease of
adenosine concentration in DBS was observed (see Table S2).
Liver biopsies
Liver biopsies were taken from five patients. Signs of chole-
stasis were described (2 patients), a reduced number of bile
ducts (2) and mild lobular hepatitis (1). Four patients showed
portal or periportal fibrosis (already observed at the age of
1 month in patient 1). In one patient, paraffin blocks of two
liver biopsies were available for further immunohistochemical
and ultrastructural studies. Immunohistochemistry for
perilipins, markers for hepatocyte steatosis, demonstrated pro-
nounced long-standing microvesicular steatosis as well as
some ballooned cells as a sign of steatohepatitis. In transmis-
sion electron microscopy, numerous small lipid droplets and
large areas of glycogen deposits were detected as well as some
polymorphic lysosomes (Fig. 3).
Discussion
This study describes the clinical phenotype of 11 newly iden-
tified patients with ADK deficiency from eight families. Hith-
erto this disease has been described in six patients from three
families. Together with those previous observations our report
significantly enlarges and defines the complex clinical find-
ings of this disease, which is likely to remain undiagnosed in
many cases because of the different and varying facets. All
patients share the clinical features of psychomotor retardation,
muscular hypotonia and frontal bossing. All but one family
presented with hepatic involvement that manifested as
prolonged or severe hyperbilirubinaemia in the neonatal peri-
od and recurrent liver crises with elevated transaminases and/
or cholestasis in the further course, which were most severe in
the first year of life. The best markers for laboratory diagnosis
appear to be elevations of AdoMet and AdoHcy in plasma, the
investigation of which is unfortunately only performed in very
few specialized metabolic laboratories in the world.
Fig. 2 Dysmorpholgical
symptoms inADK deficiency. a-d
Patient 3. a) Age 1.2 years. Icterus
is evident, frontal bossing may be
noticed. Hair is sparse and of
abnormal texture. b-d) Age
4.25 years. Facial expression of a
mentally retarded girl, frontal
bossing is pronounced. Severe
muscular hypotonia of head,
trunk and limbs. e) Patient 6, aged
22 years. He has short stature
(151 cm / -4.5 SDS),
macrocephaly (3.9 SDS) and has
a long, trigonal face with frontal
bossing. Teeth are distorted.
Slender hands and fingers can be
noted. f, g Patient 11. f) Age
14 months. Frontal bossing is
prominent. g) Age 2.3 years.
Relative macrocephaly, frontal
bossing and muscular hypotonia
278 J Inherit Metab Dis (2016) 39:273–283
T
ab
le
2
L
ab
or
at
or
y
pa
ra
m
et
er
s
P
at
ie
nt
,f
am
ily
M
et
hi
on
in
e
(μ
m
ol
/L
);
ra
ng
e
m
in
-m
ax
A
do
M
et
(n
m
ol
/L
)
A
do
H
cy
(n
m
ol
/L
)
tH
cy
(μ
m
ol
/L
)
A
de
no
si
ne
in
ur
in
e
(m
m
ol
/M
ol
C
re
a)
U
ri
c
ac
id
(μ
m
ol
/L
)
A
L
A
T
(U
/L
)
A
SA
T
(U
/L
)
IN
R
G
am
m
a-
G
T
(U
/L
)
To
ta
lb
ili
ru
bi
n
(μ
m
ol
/L
)
D
ir
ec
t
bi
lir
ub
in
(μ
m
ol
/L
)
C
K
(U
/L
)
O
th
er
s
1,
I
56
-1
07
35
5
22
5
n.
a.
n.
a.
51
2
46
61
Q
ui
ck
‘s
va
lu
e
37
%
a
11
1
28
5.
6b
23
.8
b
n/
a
m
ild
to
m
od
er
at
e
hy
pe
ra
m
m
on
em
ia
(8
0-
14
0
μ
m
ol
/L
)
2,
I
20
-4
00
21
2
15
4
12
22
70
2
46
9
98
5
7
42
9
41
4.
8
b
22
3.
0
b
37
8
3,
II
26
-8
67
22
99
18
7
24
4
14
87
46
8
52
0
2.
6
48
2
74
1.
2
52
7
31
0
4,
II
I
91
0c
16
0
72
18
7
34
5
62
4
52
4
1.
15
17
42
8.
4
b
12
7.
5
b
27
5,
II
I
16
2c
81
3
15
3
10
5
34
5
14
1
85
1.
32
10
3
13
.6
n.
a.
69
6,
IV
6-
13
5
18
6
91
5.
6
n.
a.
38
0
16
0
13
0
n.
a.
38
6
22
1
85
48
7,
V
28
-1
10
0
10
00
17
0
24
n.
a.
50
1
19
92
22
25
3.
57
25
1
11
0.
8
24
.3
1
52
1
in
iti
al
ly
di
ca
rb
ox
yl
ic
ac
id
ur
ia
du
ri
ng
hy
po
gl
yc
em
ia
8,
V
I
30
-3
50
18
92
43
8
12
n.
a.
47
0
17
2
98
1.
7
31
39
.1
n.
a.
10
5
re
pe
at
ed
ly
el
ev
at
ed
le
ve
ls
of
C
3
9,
V
II
n.
d.
n.
d.
n.
d.
n.
d.
n.
d.
n.
d.
9c
16
c
1c
n.
d.
17
c
5.
1c
15
c
10
,V
II
n.
d.
n.
d.
n.
d.
n.
d.
n.
d.
n.
d.
13
c
19
c
1c
n.
d.
27
.2
c
8.
5c
n.
d.
11
,V
II
I
18
-4
36
51
0
19
0
6.
1
45
41
4
11
3
11
7
1.
2
59
0
95
2
64
6
20
9
m
ild
hy
pe
ra
m
m
on
em
ia
du
ri
ng
fi
rs
tm
on
th
s
of
lif
e
(1
00
μ
m
ol
/L
)
P
at
ie
n
ts
fr
om
B
ju
rs
el
le
ta
l
20
11
,m
ea
n
(r
an
ge
)d
68
1
(4
55
-8
86
)
43
7
(1
53
-6
77
)
81
(4
0-
12
2)
15
(6
-2
6)
8.
5
(7
.1
-
9.
9)
39
5
(3
21
-4
69
)
27
3
(1
06
-4
47
)
n.
a.
1.
4
(1
.1
-1
.7
)
n.
a.
n.
a.
n.
a.
30
8
(1
30
-7
05
)
R
ef
er
en
ce
ra
ng
e
<
45
71
-1
18
9.
3-
14
<
14
<
4
<
48
0
<
50
<
50
<
1.
2
<
50
<
20
(a
ft
er
ne
on
at
al
pe
ri
od
)
<
3.
4
<
25
0
A
ll
pa
ra
m
et
er
s
ar
e
m
ea
su
re
d
in
pl
as
m
a
an
d
ar
e
pr
es
en
te
d
w
ith
m
ax
im
um
va
lu
es
,u
nl
es
s
st
at
ed
ot
he
rw
is
e.
n.
a.
:n
ot
av
ai
la
bl
e;
n.
d.
:n
ot
de
te
rm
in
ed
.A
ll
pa
ra
m
et
er
s
w
er
e
as
se
ss
ed
w
ith
ou
tm
et
hi
on
in
e
re
st
ri
ct
ed
di
et
,e
xc
ep
ti
n
pa
tie
nt
6,
w
he
re
di
et
w
as
st
ar
te
d
at
bi
rt
h.
tH
cy
:t
ot
al
ho
m
oc
ys
te
in
e.
a
IN
R
no
ta
va
ila
bl
e.
b
du
ri
ng
ne
on
at
al
pe
ri
od
.c
on
ly
on
e
m
ea
su
re
m
en
t
av
ai
la
bl
e.
d
re
fe
rr
in
g
to
m
ax
im
um
va
lu
es
of
th
e
pa
tie
nt
s
pu
bl
is
he
d
by
(B
ju
rs
el
le
ta
l2
01
1)
J Inherit Metab Dis (2016) 39:273–283 279
Neurological phenotype
The patients described by Bjursell et al (Bjursell et al 2011)
developed epilepsy early in the disease course (mean age
18.2 months, range 10 - 35). In our study, age at onset varied
between 4 months to 8.1 years, and some patients have
remained seizure free until now. Thus, epilepsy is frequent
in ADK deficiency but is more variable than initially de-
scribed. The mechanism of brain damage in ADK deficiency
is unclear; however, it is likely to involve lack of energy me-
tabolites (ATP), inhibition of transmethylation reactions like
DNA and protein methylation and alteration of adenosine sig-
nalling via adenosine receptors. Adenosine is an endogenous
modulator of neuronal excitability (Dunwiddie 1980) and
through adenosine receptors (A1, A2A, A2B, A3), which
partly interact with other G protein-coupled receptors, adeno-
sine affects all major neurotransmitter and neurotrophin sys-
tems (Sebastiao and Ribeiro 2009). Since the last decade,
adenosine has been considered an endogenous anticonvulsant
and neuroprotectant (Boison et al 2010). Adenosine kinase
overexpression (e.g. due to astrogliosis) and, as a conse-
quence, adenosine depletion were shown to be epileptogenic,
whereas a surge of adenosine through trauma or hypoxia in-
duced ADK deficiency was neuroprotective (Boison 2012).
Adenosine augmentation therapy (through inhibition of aden-
osine kinase or delivery of adenosine) is seen as a powerful
pharmacological approach for treatment of epilepsy (Boison
2012; Theofilas et al 2011). The high rate of epilepsy among
patients with ADK deficiency however additionally suggests
an epileptogenic potential of increased adenosine concentra-
tions. Patients with SAHH deficiency do not develop epilepsy
(Baric et al 2004, 2005). which underscores a pathogenic role
of adenosine for epilepsy in ADK deficiency. Maintaining a
balanced system of adenosine signalling should be kept in
mind for further approaches of adenosine augmentation
therapy.
As creatine synthesis depends on AdoMet-mediated meth-
ylation and accounts for a about 40 % of whole body AdoMet
Fig. 3 Representative histology
and ultrastructure of liver
biopsies. Liver biopsy of patient 2
revealed microvesicular steatosis,
chronic cholestasis and portal,
periportal and perisinusoidal
fibrosis (a, b). c, d: Pronounced
acute and chronic microvesicular
steatosis was demonstrated by
immunohistochemical staining
against perilipins 1 and 2 (plin1,
plin2). e, f: In electron
microscopy, hepatocytes showed
large pleomorphic lysosomes, and
small-sized cytoplasmic and
nuclear lipid inclusions.
Abbreviations: H&E:
hematoxylin&eosin-stain, TEM:
transmission electron microscopy,
PT: portal tract, emh:
extramedullary haematopoiesis,
HSC: hepatic stellate cell, LSEC:
liver sinusoidal endothelial cell;
LD(s): lipid droplet(s), ery:
erythrocyte; rER: rough
endoplasmic reticulum, bc:
ballooned cell. Bars: each
indicated in right lower corner
280 J Inherit Metab Dis (2016) 39:273–283
(Brosnan et al 2011). cerebral creatine deficiency may be con-
sidered as another player contributing to brain damage in
ADK deficiency.
Liver phenotype
Liver dysfunction in ADK deficiency varies from mild
hyperbilirubinaemia or mildly elevated transaminases to frank
liver failure. Similar to citrine deficiency (OMIM #605814),
Niemann Pick type C (OMIM #257220) or mannosephosphate
isomerase deficiency (MPI-CDG, formally CDG-Ib, OMIM
#602579), ADK deficiency should be included in the metabol-
ic differential diagnosis of transient neonatal cholestasis. Fatal
neonatal liver steatosis has been described in an ADK deficient
mouse model (Boison et al 2002). In addition to steatosis, liver
biopsy of patient 2 revealed subsequent liver damage with
ballooned cells and mild inflammation indicative of
steatohepatitis, with portal and periportal fibrosis and chronic
cholestasis. Fatty acids are a major source of energy in the
neonate and mitochondrial function becomes critical for ener-
gy metabolism after birth (Chalmers et al 1997; Boison 2012).
and microvesicular steatosis may indicate mitochondrial dys-
function and deficiencies in fatty acid oxidation (Burt et al
1998; Day and James 1998). In the mouse model, decreased
concentrations of the adenine nucleotides AMP, ADP and ATP
were measured in liver tissue homogenates, suggesting energy
deficiency as a possible mechanism for liver steatosis in ADK
deficiency. Reduced methylation through AdoHcy mediated
inhibition of transmethylation reactions was discussed as an-
other mechanism (Boison et al 2002). The clearly elevated
concentrations of AdoMet likely indicate an inhibition of
transmethylation reactions in our patients.
Hypoglycemia
Hypoglycemia has not been reported as a clinical sign of ADK
deficiency before. However, in our patients recurrent and/or
severe hypoglycemia was one of the first and most common
symptoms. In some patients, hyperinsulinism could be detect-
ed as the cause of recurrent hypoglycemia. Inhibitors of ADK
and adenosine agonists were recently shown to specifically
promote replication of primary β-cells of the pancreas in vitro
and in vivo through the adenosine receptor A2aa and activation
of the mTOR pathway (Annes et al 2012; Andersson et al
2012). Our finding of hyperinsulinism in patients with ADK
deficiency suggests that adenosine signalling may influence
insulin secretion in humans. Increased glycogen deposits as
seen in the liver biopsies studied may point to increased gly-
cogen storage (i.e. as consequence of hyperinsulinsim), but
other effects such as impairment of glycogenolysis cannot be
ruled out.
Patient 7 initially presented a picture similar to a defect of
fatty acid oxidation with dicarboxylic aciduria and
unresponsiveness to glucagon, before he developed hyperin-
sulinism. Hence, mechanisms of hypoglycemia in ADK defi-
ciency may be multilayered.
Incidence and diagnosis
The incidence of ADK deficiency is unknown. Literature re-
view of unexplained cases of hypermethioninaemia revealed
the three siblings published by Labrune et al in 1990
(Labrune et al 1990). that finally proved to be sisters of one
of our patients (see case report family IV in the Supplementary
Appendix). Genetic confirmation has not been done in the three
older sisters, but as they show a typical clinical and biochemical
picture and are siblings of a genetically confirmed case of ADK
deficiency, this “familial hypermethioninemia” can be consid-
ered to be ADK deficiency. Thus up to now, including the
patients published by Bjursell et al, Labrune et al (Bjursell
et al 2011; Labrune et al 1990) and the patients of this publica-
tion, 20 individuals with ADK deficiency are known, of whom
18 are alive at time of report. We expect ADK deficiency to be
an underdiagnosed disease for several reasons: the disease is
only known to a few specialists, it has a wide range of clinical
phenotypes and most biochemical findings can be intermittent,
especially hypermethioninaemia, and measurement of the most
sensitive parameters AdoMet andAdoHcy is only performed in
very few specialized metabolic laboratories. It is likely that so
far the severe end of the phenotype has been described and
family VIII suggests that there are patients with ADK deficien-
cy among individuals with intellectual disability without other
organ manifestations. Ethnical diversity of our patients under-
lines that this disease is not a regional phenomenon.
ADK deficiency is characterized by the pattern of elevated
concentrations ofmethionine, AdoMet and AdoHcy in plasma
and adenosine in urine. However, concentrations of methio-
nine and adenosine can be normal. Measurement of AdoMet
and AdoHcy in plasma appears to be more sensitive than
methionine in plasma, as AdoMet has been elevated at all
times in our patients (also in the initially described patients).
AdoHcy also has been elevated in all our patients, but was
normal in one of the patients described by Bjursell (Bjursell
et al 2011). Hypermethioninemia is often secondary to liver
disease. However, if there is isolated hypermethioninemia or
when there is a clinical suspicion of ADK deficiency, AdoMet
and AdoHcy should be measured for further differentiation.
Adenosine in dried blood spots as a potential biomarker in
newborn screening requires further study.
Therapeutic approach
Taking into account the three patients that were published
by Labrune et al (Labrune et al 1990). there is evidence for a
positive effect of a low methionine diet in ADK deficiency in
seven patients from different centres while there are no reports
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of adverse side effects apart from diarrhoea in one patient.
Especially the liver phenotype seems to improve, whereas a
positive effect on the neurological outcome has been reported
in a single case so far. Decreased intake of methionine resulted
in a clear biochemical response as measured in blood
(Table S2 and Fig. S1). It is tentative to speculate that the
dietary intervention may also normalize AdoMet and AdoHcy
in CSF. The patients described by Bjursell et al had elevated
concentrations of AdoMet and AdoHcy in CSF without diet
(Bjursell et al 2011) whereas patient 7 of this study had normal
concentrations of AdoMet and AdoHcy in CSF on diet; how-
ever, these concentrations have not been assessed before start
of the diet in patient 7. The mechanism of the effect of the low
methionine diet remains to be studied but it seems reasonable
that reduced abnormalities of the key metabolites adenosine,
AdoHcy and AdoMet will have a positive effect on the dis-
turbed metabolism in the disorder. The murine ADK deficient
model displayed reduced ADP and ATP concentrations, and
the implications of a reduction of adenosine on these cellular
key-metabolites are hard to predict. An alternative approach to
reduce adenosine levels would be through activating alterna-
tive pathways for its degradation. A recombinant ADA en-
zyme supportive therapy (already available for ADA-SCID
patients) may be a future therapy option for patients with
ADK deficiency and should be evaluated in the murine
ADK deficient model.
Experience gathered so far indicates that diazoxide is an
effective treatment of recurrent hypoglycemia caused by hy-
perinsulinism in ADK deficiency.
Here we present 11 new patients from eight families with
ADK deficiency, which were identified since the first descrip-
tion of the disorder in 2011. The facets and spectrum of disease
are defined, and ADK deficiency should be suspected in infants
with (transient) cholestatic liver disease and muscular hypoto-
nia, epilepsy or other neurological symptoms, especially when
there is also recurrent hypoglycemia and frontal bossing. How-
ever, the absence of hepatic or metabolic symptoms does not
rule out ADK deficiency. Hypermethioninaemia, increased
AdoMet and AdoHcy concentrations in plasma and increased
adenosine concentration in urine point to ADK deficiency bio-
chemically. As plasma methionine and adenosine in urine can
be normal, measurement of AdoMet and AdoHcy is of special
importance. Confirmatory diagnostics can be achieved through
molecular genetics of the ADK gene.
A low methionine diet should be considered as a therapeu-
tic option as most patients showed an improvement of
hepatopathy and as there is a potential beneficial effect on
neurological outcome, whereas diazoxide is effective to treat
hyperinsulinism. Prospective registries such as E-HOD
(http://www.e-hod.org) will give further insight into the
natural history of this most interesting inborn error of
metabolism, which affects both the methionine cycle
and adenosine metabolism.
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